注册号:
Registration number:
ChiCTR2600125405 最近更新日期:
Date of Last Refreshed on:
2026-05-26 16:40:50 注册时间:
Date of Registration:
2026-05-26 00:00:00 注册号状态:
预注册Registration Status:
Prospective registration注册题目:
一项评价 TRCN-1023 鞘内注射治疗肌萎缩侧索硬化症的安全性、耐受性、药代动力学和药效学的临床研究Public title:
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecal Administration of TRCN-1023 in Patients with Amyotrophic Lateral Sclerosis注册题目简写:English Acronym:研究课题的正式科学名称:
一项评价 TRCN-1023 鞘内注射治疗肌萎缩侧索硬化症的安全性、耐受性、药代动力学和药效学的临床研究Scientific title:
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecal Administration of TRCN-1023 in Patients with Amyotrophic Lateral Sclerosis研究课题代号(代码):
Study subject ID:在二级注册机构或其它机构的注册号:
The registration number of the Partner Registry or other
register:申请注册联系人:
陈玮琪
研究负责人:
王伊龙 Applicant:
Weiqi Chen
Study leader:
Yilong Wang 申请注册联系人电话:
Applicant telephone:
+86 10 5997 6247
研究负责人电话:
Study leader's telephone:
+86 10 5997 6247申请注册联系人传真 :
Applicant Fax:
研究负责人传真:
Study leader's fax:申请注册联系人电子邮件:
Applicant E-mail:
weiqichen@aliyun.com
研究负责人电子邮件:
Study leader's E-mail:
yilong528@aliyun.com申请单位网址(自愿提供):
Applicant website(voluntary supply):
研究负责人网址(自愿提供):
Study leader's website(voluntary supply):申请注册联系人通讯地址:
北京市丰台区南四环西路119号
研究负责人通讯地址:
北京市丰台区南四环西路119号Applicant address:
No. 119, South Fourth Ring Road West, Fengtai District, Beijing
Study leader's address:
No. 119, South Fourth Ring Road West, Fengtai District, Beijing申请注册联系人邮政编码:
Applicant postcode:
研究负责人邮政编码:
Study leader's postcode:申请人所在单位:
首都医科大学附属北京天坛医院Applicant's institution:
Beijing Tiantan Hospital, Capital Medical University研究负责人所在单位:
首都医科大学附属北京天坛医院Affiliation of the Leader:
Beijing Tiantan Hospital, Capital Medical University是否获伦理委员会批准:
是Approved by ethic committee:
Yes伦理委员会批件文号:
Approved No. of ethic committee:
KY2026-013-02
伦理委员会批件附件:
Approved file of Ethical Committee:
查看附件View批准本研究的伦理委员会名称:
首都医科大学附属北京天坛医院医学伦理委员会Name of the ethic committee:
IRB of Beijing Tiantan Hospital, Capital Medical University伦理委员会批准日期:
Date of approved by ethic committee:
2026-01-19 00:00:00伦理委员会联系人:
徐灵灵Contact Name of the ethic committee:
Lingling Xu伦理委员会联系地址:
北京市丰台区南四环西路119号Contact Address of the ethic committee:
No. 119, South Fourth Ring Road West, Fengtai District, Beijing伦理委员会联系人电话:
Contact phone of the ethic committee:
+86 10 5997 5692
伦理委员会联系人邮箱:
Contact email of the ethic committee:研究实施负责(组长)单位:
首都医科大学附属北京天坛医院Primary sponsor:
Beijing Tiantan Hospital, Capital Medical University研究实施负责(组长)单位地址:
北京市丰台区南四环西路119号Primary sponsor's address:
No. 119, South Fourth Ring Road West, Fengtai District, Beijing试验主办单位(项目批准或申办者):
Secondary sponsor:
国家:
中国
省(直辖市):
北京市
市(区县):
Country:
China
Province:
Beijing
City:
单位(医院):
首都医科大学附属北京天坛医院
具体地址:
北京市丰台区南四环西路119号
Institution
hospital:
Beijing Tiantan Hospital, Capital Medical University
Address:
No. 119, South Fourth Ring Road West, Fengtai District, Beijing经费或物资来源:
Trace Neuroscience Inc.;元羿生物医药(上海)有限公司Source(s) of funding:
Trace Neuroscience,Inc.; Tenacia Biopharmaceuticals (Shanghai) Co.. Ltd.研究疾病:
肌萎缩侧索硬化症 Target disease:
Amyotrophic Lateral Sclerosis研究疾病代码:Target disease code:研究类型:
干预性研究Study type:
Interventional study研究所处阶段:
其它 Study phase:
N/A研究设计:
单臂 Study design:
Single arm 研究目的:
评价 TRCN-1023 鞘内(IT)注射给药用于肌萎缩侧索硬化(PlwALS)患者治疗的安全性、耐受性、药代动力学(PK)和药效学 (PD)。 Objectives of Study:
To evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intrathecal (IT) administration of TRCN-1023 in People living with Amyotrophic Lateral Sclerosis (PlwALS).药物成份或治疗方案详述:
Description for medicine or protocol of treatment in
detail:
纳入标准:Inclusion criteria排除标准:
1. 确认为致病性或可能致病性SOD1和FUS基因突变携带者。
2. 在首次筛选访视前3个月内的任何时间进行过气管造口术,或任何类型的持续辅助通气。
3. 存在非ALS引发的显著肺部疾病,可能使呼吸功能评价变得复杂。允许应用间歇性无创通气。
4. 使用膈肌起搏器的患者。
5. 言语交流困难至无法正常交流、理解或听从指令、无法配合治疗及评估者。
6. 已知患有其他已知与运动神经元功能障碍相关、可能会混淆或模糊ALS诊断的疾病。
7. 妊娠或哺乳期女性;或有生育能力但未采取充分避孕措施的女性。
8. 存在任何脑部MRI扫描禁忌症,例如体内装有起搏器、动脉瘤夹、人工心脏瓣膜、植入器、金属碎片,或眼、皮肤及体内存在其他会妨碍进行脑部MRI扫描的外来物,有幽闭恐惧症等。
9. 存在腰椎穿刺、IT注射的任何禁忌症,包括但不限于:
a. 出现有临床意义的血小板减少症(血小板计数<100,000/mm^3)或其他凝血紊乱(包括但不限于正在接受香豆素类抗凝剂或低分子量肝素治疗的研究参与者,以及诊断为血友病、凝血因子X缺乏或血管性血友病的研究参与者)。
(注:筛选时的INR、PT、aPTT和血小板计数,应作为腰椎穿刺禁忌评估的一部分进行审查。)
b. 在TRCN-1023每次给药前和每次给药后24小时内,因研究参与者正在接受药物,无法在推荐的时间段内安全地中断抗血小板治疗。如有疑问,研究者应就停药期与课题委托方进行咨询。
c. 在TRCN-1023每次给药前和每次给药后12小时内,因研究参与者正在接受药物,无法在推荐的时间段内安全地中断每日抗凝剂治疗。如有疑问,研究者可就停药期与课题委托方进行咨询。
d. 存在任何颅内压(ICP)增高体征和/或症状(例如疑似颅内占位性病变),且可能影响鞘内给药(IT)安全性或干扰安全性评估的情况。
e. 既往进行过脊柱手术,可能使蛛网膜下腔入路变得复杂。
10. 存在可能干扰TRCN-1023给药安全性评估的临床显著实验室检查结果(包括但不限于以下所列)。若在筛选期间报告并确认临床显著实验室异常,可推迟TRCN-1023给药(最长延期4周)以待实验室指标恢复正常。若研究者建议更长时间延迟给药,需与课题委托单位协商。需特别注意:若研究者判定某项实验室结果无临床显著性,但该结果符合排除标准,则潜在研究参与者可获得一次复测机会。
a. 丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、血清胆红素升高(>3×正常值上限[ULN])。
值得注意的是:仅AST升高(>3×ULN),血清胆红素和ALT正常,但肌酸激酶升高不属于排除标准。
b. γ-谷氨酰转移酶升高(>3×ULN)。
c. 总胆红素(Tbil)>2×ULN。
d. 血清肌酐升高(>2×ULN)。
e. 估计肾小球滤过率(eGFR,慢性肾脏病流行病学协作组[CKD-EPI]公式计算)<60 mL/min/1.73 m^2。
f. 血红蛋白水平<9 g/dL(90 g/L)。
g. 中性粒细胞绝对计数<1,000个细胞/μL。
11. 存在严重心功能不全:符合美国纽约心脏病学会(NYHA)心功能分级III/IV级。
12. 患有传染病:包括人类免疫缺陷病毒(HIV)、肝炎、梅毒等。
13. 在计划的TRCN-1023给药前7天内接种过疫苗。如果试验期间需要接种疫苗,但无法遵守上述时间安排,则应与Trace讨论接种疫苗事宜。
14. 出现具有临床意义的心电图(ECG)异常,包括但不限于(基于重复三次记录的平均值):
a. 采用Fridericia公式(QTcF)校正的Q波和T波间期延长(男性>450 ms,女性>470 ms)。
b. QRS波或T波的形态出现异常,研究者评估后认为可能导致QT间期评估结果不可靠。
c. 存在长QT综合征的症状,或有心律失常类疾病个人史,或存在尖端扭转型室速和/或猝死的风险因素,包括症状性心动过缓、血钾过少或血镁过少,以及存在先天性QT间期延长。
15. 既往试验药物和其他药物
a. 患者同时参与了其他临床试验或仍在其他临床试验随访期内,或应用其他正在研究的生物制剂、药物或器械等。
b. 在首次筛选访视前4周内或TRCN-1023首次给药前的5个半衰期内(以较长者为准),参加过另一项临床试验。
c. 既往应用过小干扰核糖核酸(siRNA)、ASO、干细胞或基因疗法。
d. 在首次筛选访视前,超药品说明书使用药物或器械,用作ALS疾病修饰疗法。
f. 存在需要全身抗病毒或抗菌治疗的活动性感染,在第1天访视前至少7天无法完成治疗。如果潜在研究参与者或研究参与者在计划的TRCN-1023给药前7天内发生了感染,研究者应与课题委托方沟通,商讨TRCN-1023给药的重新安排事宜。
16. 首次筛选访视前6个月内有酒精或药物滥用或依赖史。
17. 研究参与者筛选前6个月有毒品应用史,包括大麻。
18. 重大自杀风险,定义如下:
a. 过去一年内或筛选期间或第1天访视时,哥伦比亚自杀严重程度评定量表(C-SSRS)第4项或第5项提示存在自杀想法。
b. 过去一年内有自杀行为。
c. 临床访谈期间临床评估存在重大自杀风险。
19. 根据DSM-V诊断标准确诊的其他精神性疾病。
20. 除原发疾病(ALS)外,存在可能影响试验完成的临床相关疾病(根据方案定义)。
21. 如果需要进行腰椎穿刺和IT注射,对任何局部麻醉存在禁忌症。
22. 已知对ASO过敏或不耐受。
23. 根据研究者的判断,存在可能使研究参与者不适合入选或可能干扰研究参与者参加或完成试验的任何其他疾病。
24. 在每次TRCN-1023给药前后24小时内无法戒酒的研究参与者。
25. 课题委托单位员工或承包商、或课题承担单位的研究者或直接参与本试验的研究中心人员及上述任何一方的直系亲属。直系亲属是指配偶、父母、子女或兄弟姐妹,不论是生物学关系还是合法的收养关系。Exclusion criteria:
1. Confirmed carriers of pathogenic or likely pathogenic SOD1 and FUS gene mutations.
2. Tracheostomy anytime, or continuous assisted ventilation of any type during the preceding 3 months before the first Screening Visit.
3. Significant pulmonary disorder not attributed to ALS, which may complicate the evaluation of the respiratory function. Intermittent non-invasive ventilation is permitted.
4. Use of a diaphragm pacemaker.
5. Speech or communication difficulties precluding normal communication, comprehension or adherence to instructions, or cooperation with treatment and assessments.
6. Any known history of other medical conditions associated with motor neuron dysfunction that could confound the clarity of the ALS diagnosis.
7. Pregnant or breast-feeding females; or females with childbearing potential if no adequate contraceptive measures are used.
8. Any contraindication to brain MRI scans, including presence of claustrophobia, pacemakers, aneurysm clips, artificial heart valves, implants, metal fragments, or foreign objects in the eyes, skin, or body that constitute a contraindication to having a brain MRI scan.
9. Any contraindication to lumbar puncture, IT injections, including but not limited to:
a. Clinically relevant thrombocytopenia (platelet count <100,000/mm^3) or other coagulation disorders (including, but not limited to, participants receiving coumarin-derived anticoagulants, or low-molecular-weight heparin, and participants diagnosed with hemophilia, Factor X deficiency, or Von Willebrand’s disease).
(Note: Screening INR, PT, aPTT, and platelet counts should be reviewed as part of this assessment of contraindication to lumbar puncture.)
b. Antiplatelet treatments that cannot be safely interrupted for the recommended period, depending on the medication participant is receiving, prior to the TRCN-1023 administration and for 24 hours after each TRCN-1023 administration. If in doubt, the Investigator should consult on the withholding period with the Industry Sponsor.
c. Daily use of anticoagulants that cannot be safely interrupted for the recommended period, depending on the medication participant is receiving, prior to the TRCN-1023 administration and for 12 hours after the TRCN-1023 administration. If in doubt, the Investigator can consult on the withholding period with the Industry Sponsor.
d. Any signs and/or symptoms of increased intracranial pressure (ICP), e.g., suspected intracranial mass, that would preclude safe IT administration or confound safety assessments.
e. Previous spinal surgery that could complicate access to the subarachnoid space.
10. Clinically significant laboratory findings that could confound the interpretation of the safety of the TRCN-1023 administration including, but not limited to, the list below. If clinically significant laboratory findings are reported and confirmed during the Screening Period, the TRCN-1023 administration can be postponed (by up to 4 weeks) to allow resolution of the laboratory findings. If a longer delay in TRCN-1023 administration is advised by the Investigator, the Investigator should consult with the Industry Sponsor. Of note, if Investigator considers a laboratory test result not clinically significant but it meets exclusionary criteria, potential participants may be retested once.
a. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum bilirubin elevations (>3 × upper limit of normal [ULN]).
Of note: An elevation of AST only (>3 × ULN) with normal serum bilirubin and ALT but elevated creatine kinase is not an exclusion.
b. Gamma-glutamyl transferase elevation (>3 × ULN).
c. Total bilirubin (Tbil) >2 × ULN.
d. Serum creatinine elevation (>2 × ULN).
e. Estimated glomerular filtration rate (eGFR, using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation) <60 mL/min/1.73 m^2.
f. Hemoglobin level <9 g/dL (90 g/L).
g. Absolute neutrophil count <1,000 cells/μL.
11. Presence of severe cardiac insufficiency, meeting the New York Heart Association (NYHA) Functional Classification Class III or IV.
12. Any known active infection, including but not limited to Human Immunodeficiency Virus (HIV), hepatitis, and syphilis.
13. Vaccines administered within 7 days of a scheduled TRCN-1023 administration. If a vaccination is required during the trial and the above schedule cannot be adhered to, vaccination should be discussed with Trace.
14. Clinically significant electrocardiogram (ECG) abnormalities, including, but not limited to (based on mean values from triplicate recordings):
a. Prolonged interval between Q and T wave corrected by Fridericia criteria (QTcF) interval (>450 ms for males and > 470 ms for females).
b. QRS or T wave morphology that could, in the Investigator’s opinion, render the QT interval assessment unreliable.
c. Symptoms of long QT syndrome or has a personal history of cardiac arrhythmias or risk factors for torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and the presence of congenital prolongation of the QT interval.
15. Prior investigational and other medications
a. Concurrent enrollment in any other clinical trial (including the follow-up period) or receipt of any concomitant investigational therapy (biologics, drugs, or devices).
b. Participated in another clinical trial within 4 weeks, or 5 half-lives of the first TRCN-1023 administration, whichever is greater, prior to the first Screening Visit.
c. Prior exposure to small interfering ribonucleic acids (siRNA), ASOs, stem cell or gene therapy.
d. Off-label use of drugs or devices that are being used as disease-modifying therapies in ALS prior to the first Screening Visit.
f. Active infection requiring systemic antiviral or antimicrobial therapy that will not be completed at least 7 days prior to the Day 1 Visit. If the potential participant or participant experiences an infection within 7 days of a scheduled TRCN-1023 administration, the Investigator should discuss the rescheduling of the TRCN-1023 administration with the Industry Sponsor..
16. History of alcohol or drug abuse or dependence within 6 months prior to the first Screening Visit.
17. History of drug use (including cannabis use) within the past 6 months.
18. Significant suicide risk, defined by any of the below:
a. Suicidal ideation as endorsed on items 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) within the past year or during Screening or at the Day 1 Visit.
b. Suicidal behaviors within the past year.
c. Clinical assessment of significant suicidal risk during clinical interview.
19. Diagnosis of any other psychiatric disorder, as defined by the DSM-V.
20. Any concurrent clinically relevant disease (other than ALS) that could interfere with the participant's ability to complete the study, per protocol definition.
21. Any contraindication to local anesthesia, if needed to perform lumbar punctures and IT injections.
22. Known hypersensitivity or intolerance to ASOs.
23. Any other conditions which, in the opinion of the Investigator would make the participant unsuitable for inclusion or could interfere with the participation in or completion of the trial.
24. Participants who are not able to refrain from alcohol in the 24 hours prior to and after the TRCN-1023 administration.
25. The employees or contractors of the Industry and Medical Sponsor, Investigator or site personnel directly affiliated with this trial, and the immediate families of either of these. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.研究实施时间:
Study execute time:
从
From
2026-01-01 00:00:00至
To
2027-12-31 00:00:00
征募观察对象时间:
Recruiting time:
从
From
2026-05-26 00:00:00
至
To
2027-06-30 00:00:00干预措施:
Interventions:
组别:
试验组
样本量:
25
Group:
Experimental Group
Sample size:
干预措施:
将研究参与者分配至2-3个连续的剂量组。剂量组1为10mg,剂量组2为20mg,剂量组3为30或40mg。各剂量组将首先纳入两名哨兵研究参与者,其给药时间至少间隔24小时。后续研究参与者的给药时间将由研究者决定。
干预措施代码:
Intervention:
Study participants were assigned to two or three consecutive dose cohorts. Dose group 1 was 10mg, dose group 2 was 20mg, and dose group 3 was 30 or 40mg. Each dose cohort will first include two sentinel study participants, with doses administered at least 24 hours apart. The timing of dosing for subsequent study participants will be determined by the investigator.
Intervention code:研究实施地点:
Countries of recruitment and research settings:
国家:
中国
省(直辖市):
北京市
市(区县):
Country:
China
Province:
Beijing
City:
单位(医院):
首都医科大学附属北京天坛医院
单位级别:
三甲
Institution
hospital:
Beijing Tiantan Hospital, Capital Medical University
Level of the institution:
Tertiary A测量指标:
Outcomes:
指标中文名:
一般人口学指标和临床资料
指标类型:
次要指标
Outcome:
General demographic measures and clinical data
Type:
Secondary indicator
测量时间点:
测量方法:
Measure time point of outcome:
Measure method:
指标中文名:
实验室检查数据采集
指标类型:
次要指标
Outcome:
Collection of laboratory data
Type:
Secondary indicator
测量时间点:
测量方法:
Measure time point of outcome:
Measure method:
指标中文名:
影像学评估
指标类型:
次要指标
Outcome:
Imaging examination
Type:
Secondary indicator
测量时间点:
测量方法:
Measure time point of outcome:
Measure method:
指标中文名:
重复神经刺激
指标类型:
次要指标
Outcome:
Repetitive neural stimulation
Type:
Secondary indicator
测量时间点:
测量方法:
Measure time point of outcome:
Measure method:
指标中文名:
临床有效性与功能评价
指标类型:
次要指标
Outcome:
Clinical efficacy and function evaluation
Type:
Secondary indicator
测量时间点:
测量方法:
Measure time point of outcome:
Measure method:
指标中文名:
安全性评价
指标类型:
主要指标
Outcome:
Safety evaluation
Type:
Primary indicator
测量时间点:
测量方法:
Measure time point of outcome:
Measure method:
指标中文名:
其它信息采集
指标类型:
次要指标
Outcome:
Collection of other information
Type:
Secondary indicator
测量时间点:
测量方法:
Measure time point of outcome:
Measure method:
指标中文名:
心电图
指标类型:
次要指标
Outcome:
Electrocardiogram
Type:
Secondary indicator
测量时间点:
测量方法:
Measure time point of outcome:
Measure method:采集人体标本:
Collecting sample(s)
from participants:
标本中文名:
血液
组织:
Sample Name:
Blood
Tissue:
人体标本去向
使用后保存
说明
Fate of sample:
Preservation
after use
Note:
标本中文名:
脑脊液
组织:
Sample Name:
Cerebral Spinal Fluid
Tissue:
人体标本去向
使用后保存
说明
Fate of sample:
Preservation
after use
Note:征募研究对象情况:
Recruiting status:
尚未开始
Not yet
recruiting
年龄范围:
Participant age:
最小
Min age
18
岁
years
最大
Max age
75
岁
years性别:
男女均可
Gender:
Both随机方法(请说明由何人用什么方法产生随机序列):
无Randomization Procedure (please state who
generates the
random number sequence and by what method):
None是否公开试验完成后的统计结果:
Calculated Results after the Study Completed public access:
不公开/Private盲法:
无Blinding:
None是否共享原始数据:
IPD sharing
否No共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):
无The way of sharing IPD”(include metadata and
protocol,
If use web-based public database, please provide
the
url):
None数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case
Record Form, CRF),二为电子采集和管理系统(Electronic Data
Capture, EDC),如ResMan即为一种基于互联网的EDC:
CRFData collection and Management (A
standard data collection and management system
include a CRF and an electronic data capture:
CRF数据与安全监察委员会:
Data and Safety Monitoring Committee:
暂未确定/Not yet注册人:
Name of Registration:
2026-05-26 16:40:45